Overview

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Status:
Completed
Trial end date:
2018-03-22
Target enrollment:
Participant gender:
Summary
This study evaluated and compared the efficacy and tolerability of lapatinib and letrozole, with letrozole and placebo in post-menopausal women with hormone receptor positive (ER positive and/or PgR positive) advanced or metastatic breast cancer, who had not received prior therapy for advanced or metastatic disease.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Novartis Pharmaceuticals
Treatments:
Lapatinib
Letrozole